Yes @col69 I noticed all of that as well. Especially the inferred extension of the timeline possibly needed to licence an internal DEP drug by bundling it into the 12 month expectations.
The May 2024 bad news dump webinar clearly indicated that the goal/target for a DEP licence was within 12 months (by 22 May 2025). If Starpharma were confident of this being executed then this new Bell Potter presentation would have highlighted it as a catalyst expected in the next 6 months.
It looks like SPL may be crab walking the possible licencing deal toward November 2025.
Ann: Bell Potter Healthcare Conference Presentation, page-3
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
10.0¢ |
Change
0.004(4.17%) |
Mkt cap ! $41.82M | |||
| Open | High | Low | Value | Volume |
| 9.6¢ | 10.0¢ | 9.6¢ | $12.66K | 128.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 63000 | 9.6¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 10.0¢ | 152320 | 1 |
View Market Depth
| Last trade - 16.10pm 28/07/2025 (20 minute delay) ? |
| SPL (ASX) Chart |